SEC Company Response from SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101) (STRO) — Sep 17, 2018
SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101)
Date: Sept. 17, 2018 · CIK: 0001382101 · Accession: 0001193125-18-274678
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227103
Referenced dates: September 11, 2018
Letter
September 17, 2018
ROBERT A. FREEDMAN
EMAIL: RFREEDMAN@FENWICK.COM
Direct Dial: +1 (650) 335-7292
VIA EDGAR AND OVERNIGHT DELIVERY
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: John Reynolds, Assistant Director
Irene Barberena-Meissner, Staff Attorney
Kevin Dougherty, Staff Attorney
Ethan Horowitz, Accounting Branch Chief
Wei Lu, Staff Accountant
Re: Sutro Biopharma, Inc.
Registration Statement on Form S-1 filed on August 29, 2018
File No. 333-227103
Ladies and Gentlemen:
On behalf of Sutro Biopharma, Inc. (the “Company”), we are concurrently transmitting herewith Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-227103) initially filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) on August 29, 2018 (the “Registration Statement”). In this letter, we respond to the comments of the staff of the Commission (the “Staff”) contained in the Staff’s letter dated September 11, 2018 (the “Letter”) with respect to the Registration Statement. The numbered paragraphs below correspond to the numbered comments in the Letter and the Staff’s comments are presented in bold italics. We have also enclosed with the copy of this letter that is being transmitted via overnight courier copies of Amendment No. 1 in paper format, marked to show changes from the Registration Statement as initially filed.
Risk Factors, page 13
Anti-takeover provisions in our charter documents and under Delaware law…., page 65
1. We note your revised disclosure that under your bylaws, the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Please expand your disclosure here or include a separate risk factor to discuss the risks associated with such provision.
In response to the Staff’s comment, the Company has revised its disclosure on pages 66 and 67 of Amendment No. 1.
U.S. Securities and Exchange Commission
September 17, 2018
Page
Description of Capital Stock, page 169
Restated Certificate of Incorporation and Restated Bylaw Provisions, page 173
Choice of Forum, page 174
2. We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. If this provision does not apply to actions arising under the Exchange Act, please also ensure that the exclusive forum provision in your governing documents states this clearly.
In response to the Staff’s comment, the Company has revised its disclosure on page 177 of Amendment No. 1 and has revised its restated certificate of incorporation to be effective upon completion of the Company’s initial public offering to clarify that the forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action”, would not apply to suits to enforce a duty or liability created by the Securities Exchange Act of 1934.
* * * * * * *
U.S. Securities and Exchange Commission
September 17, 2018
Page
Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (650) 335-7292, or, in his absence, Amanda Rose at (206) 389-4553.
Sincerely,
FENWICK & WEST LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 17, 2018 ROBERT A. FREEDMAN EMAIL: RFREEDMAN@FENWICK.COM Direct Dial: +1 (650) 335-7292 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: John Reynolds, Assistant Director Irene Barberena-Meissner, Staff Attorney Kevin Dougherty, Staff Attorney Ethan Horowitz, Accounting Branch Chief Wei Lu, Staff Accountant Re: Sutro Biopharma, Inc. Registration Statement on Form S-1 filed on August 29, 2018 File No. 333-227103 Ladies and Gentlemen: On behalf of Sutro Biopharma, Inc. (the “Company”), we are concurrently transmitting herewith Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-227103) initially filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) on August 29, 2018 (the “Registration Statement”). In this letter, we respond to the comments of the staff of the Commission (the “Staff”) contained in the Staff’s letter dated September 11, 2018 (the “Letter”) with respect to the Registration Statement. The numbered paragraphs below correspond to the numbered comments in the Letter and the Staff’s comments are presented in bold italics. We have also enclosed with the copy of this letter that is being transmitted via overnight courier copies of Amendment No. 1 in paper format, marked to show changes from the Registration Statement as initially filed. Risk Factors, page 13 Anti-takeover provisions in our charter documents and under Delaware law…., page 65 1. We note your revised disclosure that under your bylaws, the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Please expand your disclosure here or include a separate risk factor to discuss the risks associated with such provision. In response to the Staff’s comment, the Company has revised its disclosure on pages 66 and 67 of Amendment No. 1. U.S. Securities and Exchange Commission September 17, 2018 Page 2 Description of Capital Stock, page 169 Restated Certificate of Incorporation and Restated Bylaw Provisions, page 173 Choice of Forum, page 174 2. We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. If this provision does not apply to actions arising under the Exchange Act, please also ensure that the exclusive forum provision in your governing documents states this clearly. In response to the Staff’s comment, the Company has revised its disclosure on page 177 of Amendment No. 1 and has revised its restated certificate of incorporation to be effective upon completion of the Company’s initial public offering to clarify that the forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action”, would not apply to suits to enforce a duty or liability created by the Securities Exchange Act of 1934. * * * * * * * U.S. Securities and Exchange Commission September 17, 2018 Page 3 Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (650) 335-7292, or, in his absence, Amanda Rose at (206) 389-4553. Sincerely, FENWICK & WEST LLP /s/ Robert A. Freedman Robert A. Freedman Partner cc: William J. Newell, Chief Executive Officer Edward Albini, Chief Financial Officer Sutro Biopharma, Inc. Amanda L. Rose Fenwick & West LLP David Peinsipp Charles S. Kim Andrew S. Williamson Cooley LLP